# A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

> **NCT07592689** · PHASE3 · RECRUITING · sponsor: **Definium Therapeutics US, Inc.** · enrollment: 165 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **OTHER:** Placebo
- **DRUG:** DT120

## Key facts

- **NCT ID:** NCT07592689
- **Lead sponsor:** Definium Therapeutics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-10
- **Primary completion:** 2027-09
- **Final completion:** 2028-06
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07592689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07592689, "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT07592689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*